| Ticker | DSGN |
|---|---|
| ISIN | US25056L1035 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a...
Design Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.